{
    "xml": "<topic id=\"PHP2244\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/pimozide\" basename=\"pimozide\" title=\"PIMOZIDE\">\n<title>PIMOZIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_369\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/pimozide\">Pimozide</xref>\n</p>\n<data name=\"vtmid\">108438008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_182743901\" title=\"Antipsychotics (first-generation)\">Antipsychotics (first-generation)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" title=\"ANTIPSYCHOTIC DRUGS\" namespace=\"/drug-classes/antipsychotic-drugs\">ANTIPSYCHOTIC DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP48589\" outputclass=\"indicationsAndDose\" rev=\"1.25\" parent=\"/drugs/pimozide\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Schizophrenia</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 2&#8239;mg daily, adjusted according to response, then increased in steps of 2&#8211;4&#8239;mg at least every 1&#8239;week; usual dose 2&#8211;20&#8239;mg daily.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 1&#8239;mg daily, adjusted according to response, increased in steps of 2&#8211;4&#8239;mg at least every 1&#8239;week; usual dose 2&#8211;20&#8239;mg daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Monosymptomatic hypochondriacal psychosis</p>\n<p outputclass=\"therapeuticIndication\">Paranoid psychosis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 4&#8239;mg daily, adjusted according to response, then increased in steps of 2&#8211;4&#8239;mg at least every 1&#8239;week; maximum 16&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 2&#8239;mg daily, adjusted according to response, increased in steps of 2&#8211;4&#8239;mg at least every 1&#8239;week; maximum 16&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48658\" outputclass=\"contraindications\" rev=\"1.12\" parent=\"/drugs/pimozide\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">CNS depression</ph>; <ph outputclass=\"contraindication\">comatose states</ph>; <ph outputclass=\"contraindication\">history of arrhythmias</ph>; <ph outputclass=\"contraindication\">history or family history of congenital QT prolongation</ph>; <ph outputclass=\"contraindication\">phaeochromocytoma</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48500\" outputclass=\"sideEffects\" rev=\"1.10\" parent=\"/drugs/pimozide\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hyponatraemia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Glycosuria</ph>; <ph outputclass=\"sideEffect\">serious arrhythmias</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>Less sedating.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48554\" outputclass=\"pregnancy\" parent=\"/drugs/pimozide\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48728\" outputclass=\"breastFeeding\" parent=\"/drugs/pimozide\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p>\n<p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p>\n<p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48623\" outputclass=\"hepaticImpairment\" parent=\"/drugs/pimozide\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Can precipitate coma.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48530\" outputclass=\"renalImpairment\" parent=\"/drugs/pimozide\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48439\" outputclass=\"monitoringRequirements\" parent=\"/drugs/pimozide\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p outputclass=\"title\">ECG monitoring</p>\n<p>Following reports of sudden unexplained death, an ECG is recommended before treatment. It is also recommended that patients taking pimozide should have an annual ECG (if the QT interval is prolonged, treatment should be reviewed and either withdrawn or dose reduced under close supervision) and that pimozide should not be given with other antipsychotic drugs (including depot preparations), tricyclic antidepressants or other drugs which prolong the QT interval, such as certain antimalarials, antiarrhythmic drugs and certain antihistamines and should not be given with drugs which cause electrolyte disturbances (especially diuretics).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2244-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/pimozide\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74844\" title=\"Tablet\" namespace=\"/drugs/pimozide/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78155\" namespace=\"/treatment-summaries/psychoses-and-related-disorders\" title=\"Psychoses and related disorders\" count=\"1\" rel=\"backlink\">Psychoses and related disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78531\" namespace=\"/treatment-summaries/parkinsons-disease-and-related-disorders\" title=\"Parkinson&#8217;s disease and related disorders\" count=\"1\" rel=\"backlink\">Parkinson&#8217;s disease and related disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_369\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/pimozide\" title=\"Pimozide\" count=\"1\" rel=\"link\">Pimozide</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" namespace=\"/drug-classes/antipsychotic-drugs\" title=\"ANTIPSYCHOTIC DRUGS\" count=\"1\" rel=\"link\">ANTIPSYCHOTIC DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74844\" namespace=\"/drugs/pimozide/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP2244",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/pimozide",
    "basename": "pimozide",
    "title": "PIMOZIDE",
    "interactants": [
        {
            "id": "bnf_int_369",
            "label": "Pimozide"
        }
    ],
    "vtmid": "108438008",
    "drugClassification": [
        "Antipsychotics (first-generation)"
    ],
    "inheritsFromClass": [
        "ANTIPSYCHOTIC DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Schizophrenia",
                        "html": "Schizophrenia"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 2 mg daily, adjusted according to response, then increased in steps of 2&#8211;4 mg at least every 1 week; usual dose 2&#8211;20 mg daily.",
                        "html": "<p>Initially 2&#8239;mg daily, adjusted according to response, then increased in steps of 2&#8211;4&#8239;mg at least every 1&#8239;week; usual dose 2&#8211;20&#8239;mg daily.</p>"
                    },
                    {
                        "textContent": "Initially 1 mg daily, adjusted according to response, increased in steps of 2&#8211;4 mg at least every 1 week; usual dose 2&#8211;20 mg daily.",
                        "html": "<p>Initially 1&#8239;mg daily, adjusted according to response, increased in steps of 2&#8211;4&#8239;mg at least every 1&#8239;week; usual dose 2&#8211;20&#8239;mg daily.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Monosymptomatic hypochondriacal psychosis",
                        "html": "Monosymptomatic hypochondriacal psychosis"
                    },
                    {
                        "textContent": "Paranoid psychosis",
                        "html": "Paranoid psychosis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 4 mg daily, adjusted according to response, then increased in steps of 2&#8211;4 mg at least every 1 week; maximum 16 mg per day.",
                        "html": "<p>Initially 4&#8239;mg daily, adjusted according to response, then increased in steps of 2&#8211;4&#8239;mg at least every 1&#8239;week; maximum 16&#8239;mg per day.</p>"
                    },
                    {
                        "textContent": "Initially 2 mg daily, adjusted according to response, increased in steps of 2&#8211;4 mg at least every 1 week; maximum 16 mg per day.",
                        "html": "<p>Initially 2&#8239;mg daily, adjusted according to response, increased in steps of 2&#8211;4&#8239;mg at least every 1&#8239;week; maximum 16&#8239;mg per day.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "CNS depression",
                "html": "CNS depression"
            },
            {
                "type": "contraindications",
                "textContent": "comatose states",
                "html": "comatose states"
            },
            {
                "type": "contraindications",
                "textContent": "history of arrhythmias",
                "html": "history of arrhythmias"
            },
            {
                "type": "contraindications",
                "textContent": "history or family history of congenital QT prolongation",
                "html": "history or family history of congenital QT prolongation"
            },
            {
                "type": "contraindications",
                "textContent": "phaeochromocytoma",
                "html": "phaeochromocytoma"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Hyponatraemia",
                        "html": "Hyponatraemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Glycosuria",
                        "html": "Glycosuria",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "serious arrhythmias",
                        "html": "serious arrhythmias",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "Less sedating.",
                "html": "<p>Less sedating.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.\n\nAnimal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.\n\nChronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.",
                "html": "<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p><p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p><p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Can precipitate coma.",
                "html": "<p>Can precipitate coma.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Start with small doses in severe renal impairment because of increased cerebral sensitivity.",
                "html": "<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "title": "ECG monitoring",
                "textContent": "Following reports of sudden unexplained death, an ECG is recommended before treatment. It is also recommended that patients taking pimozide should have an annual ECG (if the QT interval is prolonged, treatment should be reviewed and either withdrawn or dose reduced under close supervision) and that pimozide should not be given with other antipsychotic drugs (including depot preparations), tricyclic antidepressants or other drugs which prolong the QT interval, such as certain antimalarials, antiarrhythmic drugs and certain antihistamines and should not be given with drugs which cause electrolyte disturbances (especially diuretics).",
                "html": "<p>Following reports of sudden unexplained death, an ECG is recommended before treatment. It is also recommended that patients taking pimozide should have an annual ECG (if the QT interval is prolonged, treatment should be reviewed and either withdrawn or dose reduced under close supervision) and that pimozide should not be given with other antipsychotic drugs (including depot preparations), tricyclic antidepressants or other drugs which prolong the QT interval, such as certain antimalarials, antiarrhythmic drugs and certain antihistamines and should not be given with drugs which cause electrolyte disturbances (especially diuretics).</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74844",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78155",
                "label": "Psychoses and related disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78531",
                "label": "Parkinson&#8217;s disease and related disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_369",
                "label": "Pimozide",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34569",
                "label": "ANTIPSYCHOTIC DRUGS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74844",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}